FOLR1 and neoplasm: The prevalence of FRα expression in the remaining tumor samples was lower, with 50–74% FRα-positive tumor cells in 24% of tumors (n = 31) and 1–49% FRα-positive tumor cells in 28% of cases (n = 36) (Fig. 3B).